UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 6-K
------------
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
November 26, 2007
------------
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
NOVO ALLE
DK-2880, BAGSVAERD
DENMARK
(Address of principal executive offices)
------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________
Formal Notice
Novo Nordisk stock split information
As communicated on 3 August 2007 in connection with the release of Novo
Nordisk's financial results for the first six months of 2007, Novo Nordisk's
Board of Directors has approved a stock split of the Novo Nordisk B shares
listed on the OMX Nordic Exchange and the London Stock Exchange as well as of
the American Depositary Receipts (ADRs) listed on the New York Stock Exchange
(NYSE). The trading unit of the Novo Nordisk B shares listed on the stock
exchanges in Copenhagen and London will be changed from DKK 2 to DKK 1. The
ratio of B shares to ADRs listed on the NYSE will remain 1:1. These changes in
trading units will take effect as of 3 December 2007 for the Novo Nordisk B
shares and as of 17 December for the ADRs.
Further details on the stock split
On 3 December 2007, the Novo Nordisk A/S B shares traded on the OMX Nordic
Exchange and on the London Stock Exchange will be split into two shares. The
last day of trading in the old shares will be 30 November 2007 and the first day
of trading in the new shares will be 3 December 2007. The record date is 30
November 2007.
On 17 December 2007, each of Novo Nordisk's ADRs listed on the NYSE will also be
split. On 20 December, new ADRs will be distributed in the proportion of one
additional ADR per existing ADR to ADR holders of record as of 30 November.
Hence, the ratio of B shares to ADRs listed on the NYSE will remain 1:1. The new
shares issued due to the split will be of the same type and class as the
original shares.
Due to operational reasons, from 3 December through 16 December 2007, the Novo
Nordisk B shares listed on the stock exchanges in Copenhagen and London will be
traded post-split whereas the ADRs listed on the NYSE will be traded pre-split.
Post-split trading on the NYSE will start on 17 December 2007.
JPMorgan, the depositary bank of Novo Nordisk's ADRs, will not execute issuances
and/or cancellations of ADRs between close of business 29 November and close of
business 19 December 2007. However, the trading of Novo Nordisk's ADRs on the
NYSE will continue as normal.
Novo Nordisk is a healthcare company and a world leader in diabetes care. The
company has the broadest diabetes product portfolio in the industry, including
the most advanced products within the area of insulin delivery systems. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 25,800 employees in
79 countries, and markets its products in 179 countries. Novo Nordisk's B shares
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed
on the New York Stock Exchange under the symbol 'NVO'. For more information,
visit novonordisk.com.
Further information:
Media:
Investors:
Outside North America:
Outside North America:
Mike Rulis
Mads Veggerby Lausten
Tel (direct): (+45) 4442 3573
Tel (direct): (+45) 4443 7919
mike@novonordisk.com
mlau@novonordisk.com
Hans Rommer
Tel (direct): (+45) 4442 4765
hrmm@novonordisk.com
In North America:
In North America:
Sean Clements
Christian Qvist Frandsen
Tel (direct): (+1) 609 514 8316
Tel (direct): (+1) 609 919 7937
secl@novonordisk.com
cqfr@novonordisk.com
Stock Exchange Announcement no 33 / 2007
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf of the
undersigned, thereunto duly authorized.
Date: November 26, 2007 NOVO NORDISK A/S
---------------------------------------------------
Lars Rebien Sorensen,
President and Chief Executive Officer